Biogen not pursuing a sale: source

While some of Biogen's peers have approached individual board directors of the company over time, nothing has been presented to Biogen's board for consideration recently, the person said on Wednesday. One reason that no formal offer has materialized is that Biogen values its portfolio of neurology drugs highly, and would expect any proposal to come with a significant premium, the person added. The Wall Street Journal reported on Tuesday, citing sources, that Allergan Plc and Merck & Co Inc h